How much funding has Brainever raised?

Brainever has raised $36.3M in total funding, most recently a Series B round.

Who are Brainever's investors?

Brainever's investors include Critical Path.

Where is Brainever headquartered?

Brainever is headquartered in Paris.

Brainever

Paris · Founded 2015 · $36.3M raised

Biotech

Headquarters: Paris
Founded: 2015
Business Model: B2B
Website: brainever.fr

Total Funding: $36.3M
Last Round: $36.3M Series BJul 2025
Rounds: 1

About

BrainEver is a Paris-based biopharmaceutical company developing a pipeline of novel therapies for patients suffering from age-related neurodegenerative diseases, including Amyotrophic Lateral Sclerosis (ALS), Parkinson's disease, and retinal conditions. Its approach, based on homeoprotein biology, aims to halt disease progression by stopping neuronal death and durably modifying the physiology and metabolism of surviving neurons. The company secured €33M in Series B funding to advance Europe's first clinical trial of its ALS treatment.

Summary

Brainever is a Biotech company based in Paris, founded in 2015. It has raised $36.3M in total across 1 round, most recently a $36.3M Series B round in Jul 2025. Investors include Critical Path.